Solid tumours comprise cancer cells that engage in continuous interactions with non-
malignant cells and with acellular components, forming the tumour microenvironment (TME) …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

Contemporary analyses focused on a limited number of clinical and molecular biomarkers
have been unable to accurately predict clinical outcomes in pancreatic ductal …

For decades, great strides have been made in the field of immunometabolism. A plethora of
evidence ranging from basic mechanisms to clinical transformation has gradually embarked …

Pancreatic cancer (PC) is considered highly malignant due to its unsatisfying prognosis and
limited response to therapies. Immunotherapy has therefore been developed to harness the …

Background Although immune checkpoint blockade (ICB) therapy has proven to be
extremely effective at managing certain cancers, its efficacy in treating pancreatic ductal …

Pancreatic cancer is a devastating malignancy with minimal treatment options. Standard‐of‐
care therapy, including surgery and chemotherapy, is unsatisfactory, and therapies …

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that exhibits high expression
in various tumors and is associated with a poor prognosis. FAK activation promotes tumor …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which
can enhance tumor progression and spread. Here, we undertook an unbiased temporal …

The present study describes a small library of peptides derived from a potent and selective
CXCR4 antagonist (3), wherein the native disulfide bond is replaced using a side-chain to …